secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zenas BioPharma, Inc. (ZBIO)
CIK:        0001953926
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001104659-25-085982
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zenas BioPharma secures up to $300M from Royalty Pharma for obexelimab royalty
------------------------------------------------------------------------------

- Royalty Pharma pays $75M upfront; additional $75M upon INDIGO trial success, $75M on FDA approval for IgG4-RD, $75M on FDA approval for SLE.
- Royalty Pharma receives 5.5% royalty on worldwide net sales of obexelimab and certain other payments.
- Zenas expects cash to fund operations through Q1 2027; topline Phase 3 INDIGO results expected year-end 2025.
- Obexelimab is in Phase 3 for IgG4-RD, Phase 2 for RMS and SLE; potential U.S. launch in H1 2027 if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1953926/000110465925085982/0001104659-25-085982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1953926/000110465925085982/tm2524961d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-085982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer